Format: PE; Reactivity: human
Articlecode: 12-9017-71
Contents: Phycoerythrin (PE) anti-human BLyS (CD257, BAFF)
Sizes: 25 tests, 100 tests
Formulation: Phosphate buffer pH 7.2,
150 mM NaCl, 0.09% NaN3
Storage Conditions: Store at 4°C.
DO NOT FREEZE.
LIGHT-SENSITIVE MATERIAL.
Clone: 1D6
Isotype: Mouse IgG1, ê
HLDA No.: N/A
|
|
|
Available Formats of This Product
|
Cat. No.
|
Format
|
Excite
(nm)
|
Emit
(nm)
|
Reported Applications
|
14-9017
|
|
N/A
|
N/A
|
|
13-9017
|
|
N/A
|
N/A
|
|
11-9017
|
|
|
|
|
12-9017
|
|
|
|
|
Description
The 1D6 monoclonal antibody reacts with human BLyS (B lymphocyte stimulator), also known as BAFF (B cell activating factor from the TNF family), TALL-1 (TNF and apoptosis leukocyte-expressed ligand-1), THANK (TNF homologue that activates apoptosis, nuclear factor KappaB and c-Jun NH2-terminal kinase) and zTNF4. BLyS, a member of the TNF family, is a type II membrane protein that exists in both membrane-bound and soluble forms. Expression of membrane-bound BLyS on monocytes lineage is regulated by IFN-ã. BLyS acts as a potent B cell growth factor and costimulator of Ig production. BLyS transgenic mice develop severe B cell hyperplasia and autoimmune lupus-like disease characterized by the presence of autoantibodies against nuclear antigens and immune complexes deposited in the kidney. Data from animal models imply a role for BLyS in human autoimmune diseases. To date BCMA, TACI and BR3 have been identified as receptors for BLyS. APRIL, another TNF family member, and BLyS can form active heterotrimeric molecules when coexpressed and these circulating heterotrimers are present in serum samples from patients with systemic immune-based rheumatic diseases. Furthermore, it has been reported that BLyS and APRIL, share BCMA and TACI as their receptors.
Usage
For research use only, not for diagnostic or therapeutic use. The 1D6 antibody has been reported for use in flow cytometric analysis.
Applications Tested
The 1D6 antibody has been tested by flow cytometric analysis of human BLyS transfected cells. This can be used at less than or equal to 1 ìg per million cells in a 100 ìl total staining volume. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
Related Products
Cat. 12-4714 Phycoerythrin (PE) Mouse IgG1, K Isotype Control
Cat. 11-9017 FITC anti-human BLyS (CD257, BAFF) (clone 1D6)
Cat. 13-9017 Biotin anti-human BLyS (CD257, BAFF) (clone 1D6)
Cat. 14-9017 Affinity Purified anti-human BLyS (CD257, BAFF) (clone 1D6)
References
Kayagaki, N., M. Yan, et al. 2002. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 17(4): 515-24.
Roschke, V., S. Sosnovtseva, et al. 2002. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 169(8): 4314-21.
Hsu, B. L., S. M. Harless, et al. 2002. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 168(12): 5993-6.
Yan, M., J. R. Brady, et al. 2001. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol 11(19): 1547-52.
Hase H, Kanno Y, Kojima M, Hasegawa K, Sakurai D, Kojima H, Tsuchiya N, Tokunaga K, Masawa N, Azuma M, Okumura K, Kobata T. 2004. BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex. Blood. 103(6):2257-65.
|
